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of the Human c-kit Promoter
By Gyeong H. Park, Howard K. Plummer III, and Geoffrey W. Krystal
The receptor tyrosine kinase c-kit is necessary for normal
hematopoiesis, the development of germ cells and melano-
cytes, and the pathogenesis of certain hematologic and
nonhematologic malignancies. To better understand the
regulation of the c-kit gene, a detailed analysis of the core
promoter was performed. Rapid amplification of cDNA ends
(RACE) and RNase protection methods showed two major
transcriptional initiation sites. Luciferase reporter assays
using 58 promoter deletion-reporter constructs containing
u pt o3k bo f5 8sequence were performed in hematopoietic
and small-cell lung cancer cell lines which either did or did
notexpresstheendogenousc-kitgene.Thisanalysisshowed
the region 83 to 124 bp upstream of the 58 transcription
initiation site was crucial for maximal core promoter activity.
Sequence analysis showed several potential Sp1 binding
sites within this highly GC-rich region. Gel shift and DNase
footprinting showed that Sp1 selectively bound to a single
site within this region. Supershift studies using an anti-Sp1
antibody confirmed specific Sp1 binding. Site-directed muta-
genesis of the 293/284 Sp1 binding site reduced promoter-
reporter activity to basal levels in c-kit–expressing cells.
Cotransfection into Drosophila SL2 cells of a c-kit promoter-
reporter construct with an Sp1 expression vector showed an
Sp1 dose-dependent enhancement of expression that was
markedly attenuated by mutation of the293/284 site. These
results indicate that despite the fact that the human c-kit
promoter contains multiple potential Sp1 sites, Sp1 binding
is a selective process that is essential for core promoter
activity.
r 1998 by The American Society of Hematology.
C
-KIT IS THE HUMAN cellular homologue of v-kit1 which
was isolated from the Hardy-Zuckerman 4 feline sarcoma
virus.2 c-kit encodes a receptor tyrosine kinase of the type III
family which includes platelet-derived growth factor (PDGF)
and colony-stimulating factor 1 receptors and is characterized
by an intracellular split kinase domain as well as a cysteine-rich
extracellular region. c-kit maps to the murine White Spotting
(W) locus,3,4 and its ligand, known as mast cell growth factor,
Kit ligand, or stem cell factor5 (SCF) maps to the mouse Steel
(Sl) locus.6-8 Kit and SCF interaction is involved in the
development of melanocytes, germ cells, and hematopoietic
cells. Mutations of the mouse W locus and the Sl locus lead to
severe defects in hematopoiesis and deﬁciencies in mast cells,
as well as unpigmented coats and sterility.9 SCF in combination
with other hematopoietic growth factors supports the prolifera-
tion and differentiation of multiple hematopoietic cell lineages
from early precursors.6,10,11 In addition to playing a preeminent
role in normal hematopoiesis, Kit may be important in regulat-
ing the growth of some hematopoietic malignancies.12 Kit and
SCF are coexpressed in a variety of solid tumors including
gynecologic tumors,13 colon tumors,14 breast tumor specimens
and tumor cell lines,15 neuroblastomas,16 and over 70% of
small-cell lung cancer (SCLC) lines and tumors.17-20 Coexpres-
sion in SCLC results in a functional autocrine growth loop.21
Sp1 is a ubiquitous transcription factor mostly associated
with TATA-less GC-rich promoters and is mainly thought to be
involvedinbasalpromoteractivitybyinteractingwithtranscrip-
tion activation factors, which may stabilize components of the
transcriptional machinery.22 Sp1 consists of three contiguous
Cys2His2 Zinc-ﬁnger domains that bind to the decanucleotide
consensus sequence 58 GGGGCGGGGC 3823,24 and similar
sequences that are referred to as GC boxes. Family members
Sp3 and Sp4 have similar structural features, and the DNA
binding domains of all three proteins are highly conserved.25
Another family member, Sp2, seems to have somewhat different
binding speciﬁcities.26 Functional analyses have shown that
Sp4, like Sp1, is a transcriptional activator, whereas Sp3 has
been shown to both repress27 and activate transcription.28,29
Studies have shown that Sp1-responsive promoters usually
contain multiple binding sites of differing DNA sequence and
Sp1 binding affinity,30-32 although Sp1 binding to a single site
seems to be sufficient for promoter activation.
Previous studies of the regulation of c-kit transcription have
characterized the mouse c-kit33 and human c-kit34-36 58 ﬂanking
sequence and have identiﬁed potential Sp1 binding sites in the
proximal promoter region. In studies of the mouse promoter,
important cis-acting elements required for cell type–speciﬁc
expression were localized within 105 bp of the transcription
initiation site (TIS), and no additional elements in over 5 kb of
58 sequence signiﬁcantly inﬂuenced activity.33 The human c-kit
promoter was found to lack a typical TATA box and contained
several potential Sp1 binding sites, as well as putative binding
sites for AP-2, Ets-domain proteins, Myb, and GATA-1.35 This
study also showed that sequences mediating cell type–speciﬁc
expression were contained within 120 bp of the TIS, which was
different from theTIS identiﬁed in the mouse promoter, and that
possible negative regulatory elements were located in the region
between 2992 and 2604.35 A more recent study found that
sequences up to 184 bp 58 of the translational initiation codon
were important for promoter activity, but the 24100 to 25500
region contained cell type–speciﬁc negative regulatory ele-
ments.36 With the possible exception of the microphthalmia
transcription factor identiﬁed by genetic studies and speciﬁcally
regulating c-kit expression in mast cells,37 and Myb36,38 and
Ets38 proteins, which seem to have effects on expression only
when they are overexpressed, no deﬁnitive binding of a
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this fact in mind along with the discrepancies over the
sequences necessary for appropriating c-kit expression, we
sought to further characterize the human c-kit promoter and
speciﬁcally determine the role of Sp1 in its regulation.
MATERIALS AND METHODS
Cell cultures. Cell lines used were as follows: c-kit–expressing
SCLC cell lines H526, H510, and WB19 and the HEL leukemia cell
line33,35; and the nonexpressing SCLC cell lines H146 and H8219 and
the Jurkat T-cell line.36 Cultures were grown in RPMI 1640 (Bio-
Whitaker,Walkersville, MD) medium supplemented with 10% fetal calf
serum (Life Technologies, Bethesda, MD), 2 mmol/L L-glutamine, and
50 U/mL penicillin-50 U/mL streptomycin. Drosophila SL2 cells were
cultured at 26°C in Schneider’s Drosophila medium (Life Technolo-
gies) containing 10% fetal calf serum (FCS).
Cloning of the c-kit promoter region. A 6-kb NotI fragment
containing 58 c-kit promoter sequence was isolated from a human
lambda (FIXII) placental library (Stratagene, La Jolla, CA) by screen-
ing with a radiolabelled 369-bp SstI-HindIII fragment of a 1.2-kb 58
partial cDNAclone (AmericanType Culture Collection clone #594931).
After primary screening, the positive plaques were puriﬁed through
quaternary platings using two different T4 polynucleotide kinase-
labeled oligonucleotides (complementary to bases 41-61 and 62-81 in
exon 11) as probes. The genomic NotI fragment hybridizing to the exon
1 probes was excised and subcloned into the pGEM5Zf(1) plasmid
vector (Promega, Madison, WI).
Cloning and characterization of c-kit mRNA primer extension
products. Cloning of c-kit mRNA primer extension products was
accomplished by using a modiﬁcation of the rapid ampliﬁcation of
cDNA ends (RACE) protocol for polymerase chain reaction (PCR)
ampliﬁcation of the 58 ends of cDNAs.39 Two oligonucleotide primers
(0.6 µg) speciﬁc for portions of the 58 sequence of c-kit (complementary
to bases 62-81 and 358-376 1) were annealed to 25 µg of WB total RNA
by incubation for 16 hours at 55°C in 10 to 20 µL of 0.4 mol/L NaCl/8
mmol/L PIPES (piperazine-N-N8-bis[2-ethansulfonic acid]) buffer (pH
6.7) in separate reactions. The primer extension was accomplished by
diluting the annealing mixture to 100 to 200 µL with the addition of
1,000 U of Moloney murine leukemia virus reverse transcriptase
(MMLV-RT) or MMLV-RT Superscript (Life Technologies) and 0.5
mmol/L deoxynucleoside triphosphate with the manufacturer-supplied
buffer. The extension reaction was performed at 37°C for 40 minutes
and terminated by heating to 90°C for 2 minutes. Ten micrograms of
RNaseAwas added, and the incubation was continued for 15 minutes at
37°C. The mixture was then made 0.5% sodium dodecyl sulfate, 30 µg
of proteinase K was added, and the incubation was continued for 15
minutes at 42°C. The primer-extended species were then phenol-
chloroform extracted, ethanol precipitated, and puriﬁed by binding to
GlassMAX (Life Technologies). The cDNA was eluted from the
GlassMAX matrix in TE [10 mmol/LTris(hydroxymethyl) aminometh-
ane-Cl, pH 7.4, 0.1 mmol/L Ethylenediamine Tetracetic acid] buffer,
tailed with dATP as described by Frohman et al,39 and repuriﬁed using
GlassMAX.
One-half of the cDNAwas diluted to 100 µLtotal volume and used in
the PCR reaction. The PCR reaction mixture contained a 0.6 to 0.8
mmol/Lconcentrationoforientation-speciﬁcprimerdesignedtohybrid-
ize 38 of the primer used for cDNA synthesis (complementary to bases
41-61 and bases 62-81, respectively1); a 0.9-mmol/L concentration of a
(dT)17 primer-adapter containing HindIII, SalI, and XhoI cloning sites
(58-GACTCGAGTCGACAAGCTTTTTTTTTTTTTTTTT-38); 50
mmol/L KCl, 10 mmol/L Tris HCl (pH 8.8), 1.5 mmol/L MgCl2,3
mmol/L dithiothreitol (DTT), 100 µg/mL bovine serum albumin; 0.2
mmol/L deoxynucleoside triphosphates; and 2.5 U of Taq polymerase
(AmpliTaq; Perkin Elmer, Norwalk, CT).Ampliﬁcation was performed
in a programmable thermal reactor by ﬁrst heating the mixture to 95°C
for 1 minute and then using a step program (95°C, 1 minute; 50°C, 2
minutes; 72°C, 2 minutes) for 35 cycles, with a ﬁnal extension for 15
minutes at 72°C. The ampliﬁed cDNA products were then phenol-
chloroform extracted, ethanol precipitated, resuspended in TE buffer,
and cut at the NarI (within exon 1) and SalI (within primer-adapter)
restriction sites. These restriction-cut cDNA products were then ligated
into either pGEM7Zf(2) or pSP70 vectors (Promega) cut with ClaI and
XhoI restriction endonucleases. The cDNA inserts were sequenced
using the dideoxynucleotide chain termination method as described in
Davis et al.40
RNase protection. A 3-kb BamHI-BamHI fragment containing the
promoter region was subcloned into a pGEM7Zf(2) vector and then cut
at a SalI restriction site 445 bases 58 of the BamHI site within exon 1 to
make a template for the generation of a riboprobe. RNase protection
assays were performed using 30 µg of total RNA as previously
described.41
Luciferase constructs. The promoter deletion constructs were made
by restriction endonuclease digestion of the 6-kb NotI clone subcloned
into the promoterless luciferase reporter plasmid pGL2:Basic (Pro-
mega). The 38 3 kb and 935 bp of the NotI fragment were ligated as
BamHI fragments into pGL2:Basic to make the 23-kb and the 2935-bp
constructs, respectively. A BglII-XhoI fragment was ligated into pGL2:
Basic to make the 2409-bp construct.ASmaI fragment was ligated into
pGL2:Basic to make the 2124-bp construct. A BamHI-NaeI fragment
was ligated into pGL2:Basic to make the 283-bp construct.All plasmid
constructs were puriﬁed by double cesium chloride gradient centrifuga-
tion and veriﬁed by sequence analysis.
Mutagenesis of the Sp1 binding site. The 2-bp mutation of 293/
284 Sp1 site in the 2124 construct (XN2mt) was performed using the
QuikChange Mutagenesis protocol (Stratagene). The oligonucleotides
usedforthissite-directedmutagenesiswere58-GGGGAGGCGAGGAG-
GTTCGTGGCCGCGCG-38 and 58-CGCGCCGGCCACGAACCTCC-
TCGCCTCCCC-38. Reinsertion of the 293/284 Sp1 site upstream of
the XN2mt construct was performed by annealing two oligonucleotides,
58 CCGGGAGGGGCGTGGCCG 38 and 58 CCGGCGGCCACGC-
CCCTC 38, which were then ligated into the 2124/XN2mt construct cut
with XmaI.
Luciferase reporter assays. Transfection was initiated by adding
DNA to 8 3 106 cells suspended in 0.4 mL in 2-mm cuvettes that were
incubated on ice for 10 minutes. H526 cells were electroporated in
phosphate-buffered saline (PBS) (pH 7.4) at 300 V and 500 µF, H146
cells in PBS at 300V/1,000 µF, HELcells in PBS at 200V/1,500 µF, and
Jurkat cells in RPMI 1640 at 300 V/1,250 µF using a BTX Electro Cell
Manipulator 600 (BTX Inc, San Diego, CA). The cells were transfected
with 25 µg of the pGL2:23-kb construct and equimolar amounts of the
smaller reporter plasmids. pSP70 plasmid was used as a ﬁller plasmid to
maintain a ﬁnal DNA concentration of 25 µg for each transfection. Ten
micrograms of pCMV bgal plasmid was cotransfected to serve as a
control for transfection efficiency. After electroporation, the cells were
plated in 6 mLof RPMI 1640/10% FCS in 60-mm tissue culture dishes,
cultured for 24 hours, and harvested according to the Reporter Lysis
protocol (Promega) using 400 µLof reporter lysis buffer. Luciferase and
b-galactosidase activities were assayed according to the manufacturer’s
protocol (Promega). Luciferase activity was analyzed using 20 µL of
cell extract mixed with 100 µLof luciferase substrate (Promega), which
was quantitated for 30 seconds in a Lumat LB 9507 luminometer
(EG&G Berthold, Bad Wildbad, Germany). b-galactosidase activity
was used to normalize for transfection efficiency. SL2 cells were
transfected using the calcium phosphate coprecipitation technique, as
described in Davis et al.40 Luciferase and b-galactosidase activity in the
SL2 cells were assayed as above.
Gel mobility shift analysis. Whole cell extracts used in this assay
were prepared in the following manner. Approximately 5 3 107 cells
were obtained, washed with PBS (pH 7.4), and resuspended in 1 mL of
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mmol/L EDTA, 0.5 mmol/L DTT, 25% glycerol, 0.5 mmol/L phenyl-
methylsulfonyl ﬂuoride). This suspension was frozen and thawed three
times using a dry ice/ethanol bath and a 37°C water bath. After a
10-minute centrifugation at 13,000g at 4°C, the supernatant was
aliquotted and stored at 270°C until use. Protein concentration was
determined by BCA assay (Pierce, Cleveland, OH). Oligonucleotides
used were as follows: Xma-Nae fragment (2124 to 283): 58-
CCGGGCGGGCGCGAGGGAGGGGAGGCGAGGAGGGGCGTG-
GCC-38 and 58-GGCCACGCCCCTCCTCGCCTCCCCTCCCTCG-
CGC-38;X N( 2 125/297): 58-CCCGGGCGGGCGCGAGGGA-38 and
58-TCGCCTCCCCTCCCTCGCGCCCGC-38; XN2 (2102/282): 58-
GGGGAGGCGAGGAGGGGCGT-38 and 58-CGGCCACGCCCCTC-
CTCG-38; the XN2 oligonucleotide with a 2-bp mutation in a putative
Sp1 site, XN2mt: 58-GGGGAGGCGAGGAGGTTCGT-38 and 58-
CGGCCACGAACCTCCTCG-38; and XN3 (296/282): 58-GGA-
GGGGCGTGGC-38 and 58-CGGCCACGCCCCT-38. Oligonucleotides
were synthesized by the MCV-VCU Nucleic Acid Synthesis Core
Facility (Richmond, VA), and Integrated DNA Technologies (Coral-
ville, IA). Consensus and mutant Sp1 oligonucleotides were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA).The oligonucleotides
were annealed; radiolabeled by ﬁll-in reaction using Klenow fragment,
dATP, dGTP, dTTP, and a32P-dCTP (3,000 Ci/mmol; NEN, Boston,
MA) or T4 polynucleotide kinase and g32P-ATP40; and unincorporated
label was removed using a Sephadex G-50 column. Ten micrograms of
H526 cell extract was incubated with 10,000 cpm of labeled DNAin 20
µL of binding buffer (20 mmol/L HEPES [pH 7.9], 1 mmol/L DTT, 1
mmol/L EDTA, 10% glycerol, 1 µg poly dI-dC, and 50 mmol/L NaCl)
for 20 minutes at room temperature. Assays with recombinant human
Sp1 (rhSp1; Promega) protein were performed in the same manner
using 1 footprinting unit (fpu) of rhSp1 added to 1 µg of Drosophila
nuclear extract (Promega). For competition assays, unlabeled competi-
tor oligonucleotides were added to the nuclear extracts 20 minutes
before addition of radiolabeled probe. Reactions were electrophoresed
at 100 V in a nondenaturing 4% polyacrylamide gel in 0.5 3
Tris-borate, EDTA(TBE) buffer40 at 4°C.
In supershift assays, 2 µg of an antibody speciﬁc for Sp1, Sp2, Sp3,
Sp4 (Santa Cruz), or nonspeciﬁc rabbit IgG (Sigma Chemical Co, St
Louis, MO) was incubated with the gel-shift mixture for 20 minutes at
roomtemperatureafternormalgel-shiftincubation.The4%nondenatur-
ing gel was run at 325 V at 4°C in 0.5 3 TBE.
DNA footprinting. Footprinting assays were performed according
to the Core Footprinting system protocol (Promega). A fragment
containing bases 2124 to 137 was cut out of the pGL2:2409-bp
construct using HindIII and SmaI. It was subsequently subcloned into
the HindIII/SmaI sites of the pSP64 plasmid vector (Promega). From
this construct, a 172-bp fragment was cut out using HindIII and EcoRI,
kinased using g32P-ATP, restriction enzyme digested with SmaI, leaving
only the 137 end of the probe labeled. Cell extracts and binding buffer
were prepared as described above. The labeled probe was incubated
with 10 or 20 µg of H526 cell extract for 20 minutes at room
temperature in a total volume of 20 µL. This mixture was digested with
1.2 U of DNase I for 1 or 2 minutes at room temperature and then run on
a 6% acrylamide, 8 mol/Lurea sequencing gel at 1,500V/60Wuntil the
bromophenol blue dye-front reached the bottom of the gel. For the
sequencing ladder, a 17-bp oligonucleotide, 58-AGCTTGGATCC-
GAGCTC-38, corresponding to the exact 58 end of the footprinting
fragment was used as a primer for sequencing of the pSP64 plasmid
containing the HindIII-SmaI insert.
RESULTS
Identiﬁcation of the transcription initiation sites. We ini-
tially used a modiﬁcation of the RACE protocol to identify the
transcriptional initiation sites using RNA isolated from the
c-kit–expressing SCLC cell line WB. Oligonucleotide primers
were annealed to WB total RNA, extended, tailed with dATP,
ampliﬁed by PCR, subcloned, and inserts were sequenced. The
transcription start site was identiﬁed as the base adjacent to the
start of the terminal transferase-generated deoxynucleotide tail.
We sequenced 11 independent clones generated from the RACE
protocol. Seven of the 11 clones identiﬁed the major initiation
sites at the nucleotide G, 58 bases upstream of the translational
initiation codon, and the nucleotide A, 56 bases upstream (Fig
1). These TIS are designated as 11 and 13 on the proximal
c-kit promoter sequence (Fig 2).
To conﬁrm the RACE study and determine the relative usage
Fig 1. RACE clones show two major transcrip-
tional initiation sites. The transcription initiation site
was identified as the base adjacent to the start of the
poly T tail. (Left panel) Transcription start site at
nucleotideG,base11inFig2.(Rightpanel)Transcrip-
tion start site at nucleotide A, base 13 in Fig 2.
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was performed. A BamHI-SalI fragment extending approxi-
mately 400 bases beyond the potential transcriptional start sites
was used to transcribe a riboprobe.This riboprobe was annealed
to total RNA isolated from cell lines that express c-kit mRNA
(WB, H510, and HEL) as well as a cell line that does not
express c-kit mRNA(H82), and an RNase protection assay was
performed.
Both the WB and H510 SCLC cell lines, which express high
levels of c-kit mRNA, were found to contain protected bands
corresponding to at least three different transcriptional start sites
(Fig 3). The two major bands correspond to the bases 11 and
13 identiﬁed by the RACE protocol (Figs 1 and 2). The third
band corresponds to base 17, a base also identiﬁed by one of
the RACE clones. We found no protected bands when our
riboprobe was annealed to either RNA from the SCLC cell line
H82, which does not express c-kit, or yeast tRNA (Fig 3). HEL
cells were found to have the identical three bands, showing that
these transcriptional start sites are common to SCLC and
hematopoietic cells (Fig 3).
Scanning of the sequence immediately upstream of the
transcription initiation sites (Fig 2) failed to reveal a TATAbox.
This region was also scanned for an initiator (Inr) promoter
element, which can also mediate transcriptional initiation at
unique sites.42 The Inr overlaps transcriptional start sites, and
has the core consensus sequence Py PyA11 N T/APy Py.43 The
c-kit transcriptional start site at base 11 corresponds to this
sequence, except guanine is substituted for adenine at 11 (Fig
2). If the c-kit transcriptional start site at base 13 is considered,
then the only differences are purines substituted for pyrimidines
at both ends of the consensus sequence.
Functionalanalysisofthehumanc-kitpromoter. Tocharac-
terize functional regulatory elements within the c-kit promoter,
we used a series of 58-deletion fragments linked to the luciferase
gene and tested them in transient transfection assays. The
promoter fragments ranging from 83 bp up to 3 kb of 58
sequencewereclonedintothepromoterlesspGL2:Basiclucifer-
ase vector. The deletion construct plasmids were electroporated
into the H526 SCLC and the HEL cell lines which express
endogenous c-kit or the H146 SCLC and the Jurkat cell lines
which do not express c-kit. Reporter assays showed the same
level of expression independent of whether the cell lines
expressed c-kit, indicating there are no cell type–speciﬁc
regulatory elements within sequences 3 kb upstream of the TIS
(Fig 4). The 283 construct showed a basal level of activity.
There was a fourfold to ﬁvefold increase in activity from the
283-bp construct to the 2124-bp construct. Additional se-
Fig 2. Nucleotide sequence of the human c-kit
promoter from 2124/137. The sequence is num-
bered from the 58 transcription initiation site. The
locations of the double-stranded oligonucleotides
(XmaI-NaeI, XN, XN2, XN3) used in gel shift analysis
(below) are indicated. The locations of potential Sp1
binding sites are indicated as lines above the se-
quence showing degree of homology to the consen-
susdecanucleotide.TheTTintheXN2mtoligonucleo-
tide marks the location of an inserted 2-bp mutation
(below). The 137 nucleotide is the most 38 base of
c-kit promoter sequence before the pGL2 polylinker
in the reporter plasmids.
Fig 3. RNase protection analysis showed multiple transcriptional
initiation sites. Two major and one minor protected bands, indicating
the transcriptional start sites, were detected in the WB and H510
SCLC cell lines as well as the HEL leukemia cell line. These respec-
tively correspond to base 11 (41 bp from 38 BamHI site), 13, and 17
in Fig 2. The upper major band comigrated with a 41-base RNA
size marker made by transcribing BamHI-cut pGEM3 with SP6
polymerase.
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reporter activity which may indicate negative regulatory se-
quences. Based on this analysis, regulatory elements respon-
sible for maximal core promoter activity must lie within the
283 to 2124 region.
Speciﬁc protein binding to the 293/284 site in the core
promoter. A search for transcription factor binding sites
within this 40 bp yielded several potential consensus binding
sites for Sp1 including a 9/10 consensus Sp1 site, GGGGC-
GTGGC (Fig 2). To characterize the proteins that bind to this
region of DNA, we performed gel mobility shift analysis (Fig
5).When oligonucleotides corresponding to the 58 and 38 halves
of the 40 bases were incubated with H526 cell extract, only the
38 half oligonucleotide (XN2) produced a strong shifted band.A
further gel shift using a smaller oligonucleotide corresponding
to the 38 15 bp (XN3) showed that only a 15-bp fragment of
DNA containing the 293/284 consensus Sp1 site is necessary
for a gel shift. This shifted band comigrates with the band
obtained using a consensus Sp1 oligonucleotide.
To show speciﬁcity, a competition assay was performed.
Incubating the XN3 oligonucleotide with unlabeled competitor
DNA containing a cognate binding site before addition of
labeled probe should compete for protein binding and result in
subsequent loss of a shifted band. Only the oligonucleotides
containingthe293/284siteandtheconsensusSp1oligonucleo-
tide were able to successfully compete for binding (Fig 6).
Neither the mutant consensus Sp1 oligonucleotide (58-
ATTCGATCGGTTCGGGGCGAGC-38) nor the oligonucleo-
tide corresponding to the 58 half of the 40-bp (XN) fragment
was able to compete for binding, which shows speciﬁc binding
by the protein to the XN3 oligonucleotide.
If the protein was bound to the 293/284 site, mutation of
this site should cause disruption of binding and loss of the
shifted band. A 2-bp mutation (GGGGCGTGGC . GGTTC-
GTGGC) was introduced into the 293/284 site in the XN2
oligonucleotide (Fig 2); gel shift analysis with this oligonucleo-
tide failed to produce a shifted band (Fig 7A). This indicates
that a protein from the H526 extract was speciﬁcally recogniz-
ing the 2-bp mutated sequence as part of its binding site.
Furthermore, incubation of the XN2 oligonucleotide with H526
extract yielded a shifted complex with the same mobility as that
of the XN2 oligonucleotide incubated with recombinant human
Fig 4. Promoter-reporter ac-
tivity of sequential 58 deletion
constructs. Promoter activity of
all promoter constructs (dia-
grammed at left) was compared
with that of pGL2:SV40 pro-
moter with transient transfec-
tion of the constructs into H526,
H146, HEL, and Jurkat cell lines.
Cotransfection with pCMV bgal
plasmid was used to control for
transfectionefficiency.Aftera24-
hour incubation, cell extracts
were assayed, normalized for
transfection efficiency, and rela-
tive reporter activity was deter-
mined. Error bars indicate stan-
dard error (SE) calculated from
at least six separate electropora-
tions. All activity values are rela-
tive to the pGL2:SV40 promoter,
which was assigned a value of
1.0. Relative reporter gene activ-
ity was calculated as follows:
luciferase activity divided by
b-galactosidase activity, divided
by the ratio obtained for the
pGL2:SV40 promoter construct.
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contain Sp1, failed to produce a shifted band. These data further
suggest that the binding protein is Sp1.
To conﬁrm the location of protein binding and to screen for
additional binding sites, a DNase footprint analysis was per-
formed.ADNAfragment containing the 2124/137 region was
58 end-labeled, incubated with H526 cell extract, and then
digested with 1.2 U of DNase I. The digestion products were
analyzed on a 6% sequencing gel. A sequencing reaction of the
identical region was run on the same gel to identify the
protected region. The region corresponding to the 293/284
consensus Sp1 was protected from DNase I digestion (Fig 8).
This was the only region shown to be protected under our assay
conditions, but it is possible that there are other protected sites
at the 58 and 38 ends of the fragment which cannot be well
visualized.
Sp1 speciﬁcally binds the 293/284 site. The above data
strongly suggest that an Sp family member binds to the
293/284 site based on the speciﬁcity of binding and mobility
of gel-shifted species. To further determine if the protein
binding to the 293/284 site was indeed Sp1, a supershift assay
was performed. If Sp1 was the binding protein, incubation of
the protein:DNA complex with an anti-Sp1 antibody should
result in a complex of slower mobility than the original shifted
band. Because the other Sp family members also bind GC
boxes, we also assayed the abilities of antibodies to Sp2, Sp3,
and Sp4 to bind to the protein:DNA complex. Incubating
32P-labeled XN2 oligonucleotide with H526 cell extract and
Sp1-speciﬁc antibody resulted in a supershifted band, whereas
incubating with antibodies speciﬁc for Sp2, Sp3, Sp4, or
nonspeciﬁc rabbit IgG did not (Fig 9), conﬁrming that Sp1
speciﬁcally binds to this region of DNA.
Mutational analysis of the 293/284 Sp1 site. The reporter
construct containing the 2124/137 region has maximal activ-
ity, likely representing the core promoter. To correlate Sp1
binding with the potency of this region to promote transcription,
we introduced a 2-bp mutation into the 293/284 Sp1 site
(GGGGCGTGGC . GGTTCGTGGC) of the 2124 construct
(XN2mt). This mutation eliminated Sp1 binding by gel-shift
analysis (Fig 7). Reporter activity of the mutant construct
transfected into H526 cells was reduced to basal levels when
compared with the wild-type construct (Fig 10). To study the
effect of restoration of the Sp1 binding site, we inserted the
wild-type 293/284 consensus site directly upstream of the
XN2mt construct (XN2mt/Sp1), which restored much of the
activity, though it was less than wild-type. This lower activity
may be related to the altered position of the Sp1 binding site in
this construct.
The above data correlates the ability of Sp1 to uniquely bind
to the 293/284 site in vitro with the ability of this site to
activate transcription in vivo. To correlate in vivo Sp1 binding
with the ability of this site to activate transcription we turned to
the Drosophila SL2 expression system.44 Courey and Tjian44
devised this system to analyze the functional domains of Sp1
because it is extremely difficult to observe the effects of
exogenously expressed Sp1 on the background of the high
constitutive levels of Sp1 in mammalian cells. Drosophila cells
lack endogenous Sp1, yet transfected reporter plasmids contain-
ing Sp1 sites show a dose response to exogenously expressed
Sp1, indicating that the conserved transcriptional machinery is
Fig 5. Gel mobility shift analysis of protein bind-
ing to the 2124 to 283 DNA fragment. Gel mobility
shift analysis was performed with the double-
stranded DNA fragment containing the 2124 to 283
region alone and with 10 mg of cellular protein from
H526 cells. The SC Sp1 oligonucleotide (Santa Cruz)
contains a consensus Sp1 binding site. The oligo-
nucleotides corresponding to c-kit sequences are:
Xma-Nae (2124/283), XN (2125/297), XN2 (2102/
282), XN3 (296/282). The 1/2 indicates whether
H526 extract was added to the gel shift mixture.
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of Sp1.44 To correlate in vivo Sp1 binding with activation of
c-kit transcription, we cotransfected into SL2 cells either the
wild-type 2124 reporter construct or the construct containing
the mutant 293/284 site with increasing amounts of a plasmid
encoding Sp1 under the control of the Drosophila actin
promoter (pPacSp1; kindly donated by R. Tjian).44 Figure 11
illustrates that transcriptional activation of the wild-type 2124
construct showed a dramatic dose response to Sp1 expression.
Transfection of the empty Drosophila expression vector, pPacU,
had no effect on expression. The mutant construct also showed
an Sp1 dose-dependent increase in transcription, but the levels
of reporter expression approached only 10% to 20% of those of
the wild-type construct. The Sp1-dependent transcription of the
mutant construct suggests that low-level transcriptional activa-
tion may be obtained through Sp1 binding to alternative sites.
However, it is clear from all the reporter assays that selective
Sp1 binding to the 293/284 site and not to the other potential
binding sites is required for maximal promoter activity.
DISCUSSION
In this study, two major transcriptional initiation sites for the
human c-kit gene were identiﬁed using the RACE protocol and
RNase protection assays, and these sites were shown to be
common to both hematopoietic and nonhematopoietic cell lines.
The human c-kit transcriptional initiation site identiﬁed in this
study as base 11 (Fig 2) is homologous to the mouse c-kit
transcriptional start site33 and with one of the major start sites
previously identiﬁed in the human promoter.35 In addition,
Yamamoto et al35 identiﬁed a transcriptional initiation site 4
basesupstreamofthissite.Wealsoidentiﬁedmultipletranscrip-
tional initiation sites, but in addition to the site at 11, we
localized the others to 13 as well as a minor site at 17 (Fig 3).
Yamamoto et al35 used an M13mp18 sequencing ladder to
determine the size of the primer-extended and S1 nuclease-
protected bands. We believe the RACE method used in this
study, which allows for direct sequencing of the primer-
extended species, gives a more accurate localization of the
transcription initiation sites. This accurate localization is a
necessary prerequisite for the identiﬁcation of elements that
regulate transcriptional initiation.
Initiator elements are known to localize transcription initia-
tion sites and mediate the action of some upstream activators in
TATA-less promoters.43 The human c-kit promoter has se-
quences centered around bases 11 and 13 that are very similar
to the initiator consensus sequence (Py Py A11 N T/A Py Py).43
Only one difference from the Inr consensus sequence is
observed for transcription starting at base 11, substituting the
guanine for adenine at the initiation site. For transcription
starting at base 13, the pyrimidines at both ends of the
consensus Inr sequence are replaced by purines. Although
substituting a guanine for adenine at base 11 substantially
weakens the Inr element,43 having two overlapping Inr se-
quences may compensate and allow transcriptional initiation at
either the 11o r1 3 position.
As mentioned earlier, there have been several studies per-
formed on both the mouse and human c-kit promoter.The initial
study of the mouse promoter found that as little as 105 bp
upstream of the TIS was enough to show strong promoter
activity in cell lines that express c-kit but not in nonexpressing
cell lines.33 In a similar study of the human c-kit promoter,
sequences 120 bp upstream of the TIS were shown to activate
the c-kit promoter in a cell type–speciﬁc manner.35 In the study
of the mouse promoter,33 the HL-60 cell line was used as the
nonexpressing cell line. We also initially used HL-60 cells but
found transfection efficiencies to be very low, making expres-
sion studies from any reporter plasmid difficult to interpret.
Therefore, we switched to the H146 and Jurkat cell lines, which,
in our hands, had much higher transfection efficiencies, and we
found no cell type–speciﬁc elements in the proximal promoter.
Fig 6. Competition assays using specific and nonspecific competi-
tor oligonucleotides. In the absence or presence of competing oligo-
nucleotides, 0.1 ng of 32P-labeled XN3 oligonucleotide was incubated
with H526 extract. Competing oligonucleotides were at 100-fold
excess. The competing oligonucleotides corresponding to c-kit se-
quences were: Xma-Nae (2124/283), XN (2125/297), XN2 (2102/
282), XN3 (296/282). Labeled DNA:protein complexes were only
formed in the presence of competitors that do not contain the
293/284 Sp1 site. Competition using the consensus Sp1 oligonucleo-
tide was used as a positive control, and the oligonucleotide contain-
ing a mutant Sp1 site (SC mt Sp1) was used as a negative control.
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the previous studies may be caused by the use of c-kit
nonexpressing cells with low transfection efficiencies.
In agreement with the studies mentioned above, our analysis
of the human c-kit promoter has shown that a construct
containing 124 bp of promoter sequence was able to maximally
activate the c-kit promoter, albeit not in a tissue-speciﬁc
manner. This ﬁnding agrees with Vandenbark et al,36 who
concluded that the DNAregion to 2183 (from the translational
initiation codon; equivalent to 2125 in our numbering scheme)
was important for c-kit promoter activation, but did not confer
cell type–speciﬁc transcription. Their data suggested that a
distal negative regulatory DNA segment between 24100 to
25500 was the main, though not the only, cis-acting DNA
A B
Fig 7. The protein in the 293/284 complex has the binding specificity and mobility of Sp1. (A) A 2-bp mutation (GGGGCGTGGC G
GGTTCGTGGC) was introduced into the 293/284 Sp1 site of the XN2 oligonucleotide (XN2mt), and binding ability was compared with the
wild-type XN2 oligonucleotide. The 2/1 indicates whether cellular extract was added to the gel shift mixture. Ten thousand cpm of the XN2 and
XN2mt oligonucleotides were incubated with 10 mg of H526 extract. (B) Mobility shift of XN2 oligonucleotide with rhSp1. Mobility shift analysis
using the XN2 oligonucleotide incubated with H526 extract (10 mg ) or with recombinant human Sp1 (rhSp1, 1 fpu) and Drosophila nuclear
extract (1 mg). Incubation of the XN2 oligonucleotide with H526 extract (lane 2) yielded a band with a similar mobility pattern as that obtained by
incubating XN2 oligonucleotide with rhSp1 and Drosophila extract (lane 3). Incubation of XN2 oligonucleotide with Drosophila extract alone was
used as a negative control (lane 4).
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showed that Myb binding to a consensus site at approximately
21300 had a negative regulatory effect. This is in contrast to a
recent study by Ratajczak et al,38 who showed that Myb and
Ets-2 binding to consensus sites located between 2179 and
2471 cooperatively enhanced transcription. However, in the
latter study overexpression of Myb and Ets-2 was required to
observe these effects; deletion of all Myb and Ets consensus
sequences had no signiﬁcant effect on expression in the
presence of endogenous levels of these two transcription
factors. Thus, as has been previously shown,36 the tissue-
speciﬁc regulation of c-kit is likely to be complex. We believe
that the difficulty in reconciling all the published data indicates
that regions of DNAcontaining major tissue-speciﬁc regulators
of transcription have yet to be identiﬁed. Recently, two studies
of the Wsh mutation found an inversion disrupting tissue-
speciﬁc positive regulatory elements controlling c-kit expres-
sion,45,46 suggesting that potential c-kit upstream regulatory
elements may lie near the breakpoint, located between the
PDGFRa and c-kit loci, within 100 to 200 kb 58 of c-kit. Our
study did not show any cell type–speciﬁc elements within the
proximal 3 kb of promoter sequence.
All proximal promoter-reporter studies performed thus far
agree that deletion of the region between 2124 and 283 from
the TIS results in a drop in promoter function to basal levels in
c-kit–expressing cells.33,35,36,38 This crucial region contains the
293/284 Sp1 binding site we have characterized, which is
completely conserved in the mouse promoter.33,37 Transfection
studies of promoter-reporter plasmids containing a mutation
which eliminated in vitro Sp1 binding resulted in a drop in
Fig 9. Supershift analysis of Sp1 family members. Interaction of
the XN2 fragment with H526 cell extracts in the absence and
presence of antibodies specific for Sp1, Sp2, Sp3, Sp4, and nonspe-
cific rabbit IgG. The DNA:protein complexes were analyzed on a 4%
nondenaturing polyacrylamide gel. The first lane contains no extract
and no antibody.
;
Fig 8. DNase footprinting analysis of the 2124 to 137 region. The
ability of proteins to bind and protect the core promoter region of the
c-kit promoter was analyzed. DNase I digestion for 1 and 2 minutes of
the 32P-labeled DNA fragment was performed with no cell extract
(lane 1) and in the presence of 10 and 20 mg of cell extract (right
panel). The digested products were analyzed on a 6% sequencing gel.
A sequencing reaction of the DNA region was run in parallel (left
panel). The sequence of the protected region, corresponding to the
293/284 SP1 site, is shown.
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284 site is largely responsible for the activity of the whole
2124/283 fragment. However, overexpression studies in SL2
cells did demonstrate that Sp1 was still able to weakly
transactivate in spite of mutation of the 293/284 site, indicat-
ing that one of the upstream consensus sites may have some
functional activity. In fact, gel-shift studies (Fig 5) have
suggested weak in vitro binding of Sp1 to the XN oligonucleo-
tide, which contains a perfect 6/6 Sp1 core consensus sequence
(GGGCGG; 2122/2117) that other investigators have identi-
ﬁed as the likely site of Sp1 binding within the 2124/283
fragment based on computer homology algorithms.33,35 Muta-
tion of this site in promoter-reporter constructs resulted in only
a 20% to 25% decrease in transcriptional activity (not shown),
consistent with our conclusion that the vast majority of Sp1-
mediated transcriptional activation occurs as a result of binding
to the 293/284 site.
There are many examples where Sp1 plays an essential role
in core promoter activity.47,48 In addition, in the human adeno-
sine deaminase promoter, Sp1 not only controls basal level
activation but is also involved in enhancer-mediated activa-
tion.49 Furthermore, in some promoters Sp1 can discriminate
between different consensus Sp1 binding sites,50 indicating that
certain Sp1 binding sites contribute more to the overall activity
than other sites. An example of a promoter that relies predomi-
nantly on only one of multiple potential Sp1 sites, in addition to
the c-kit promoter, is the promoter of the transforming growth
factor b type I receptor51 (TGF-bRI). Deletion and site-speciﬁc
mutation analyses explored the importance of multiple Sp1 sites
throughout the TGF-bRI promoter and established that one
downstream site at position 263 to 254 contributes heavily to
basal promoter activity. In the nicotinamide adenine dincucleo-
tide phosphate cytochrome P-450 oxidoreductase gene, pro-
moter deletion studies indicated that loss of the seven distal GC
boxes had minimal effect on transcriptional activity, but dele-
tion of the two proximal Sp1 sites resulted in 90% loss of
promoter activity.48 In addition, some cell type–speciﬁc promot-
ers require cooperative activity of Sp1 with cell type–speciﬁc
transcription factors, including Egr-1 for thrombospondin,52
AP2 for the acetylcholine receptor a3 gene,53 and GATA 1 for
the g-globin gene.54 Although a potential AP2 site exists on the
2124 to 283 fragment, no evidence for binding of factors other
than Sp1 was found by either gel-shift or DNase footprint
analysis.
In conclusion, we have localized the major transcriptional
initiation sites of the human c-kit gene to two bases 58 and 56
bases upstream of the translational initiation codon. Two
overlapping weak Inr consensus sites may mediate transcrip-
tional initiation at these speciﬁc sites. All the c-kit promoter
Fig 10. Functional analysis of 293/284 binding site. Reporter
assays were performed as in Fig 4. A construct containing a 2-bp
mutation of the 293/284 Sp1 (GGGGCGTGGC G GGTTCGTGGC)
site,2124XN2mt,displayedbasalreporteractivity.The2124XN2mt/
9/10 construct, which has the 293/284 Sp1 site inserted 40 bp
upstream in the 2124 XN2mt construct, restores reporter activity to
near wild-type levels.
Fig 11. In vivo transcriptional
activation mediated through the
293/284 binding site correlates
with Sp1 expression. Five micro-
grams of either the 2124 pro-
moter-reporterconstruct(WT)or
the 2124 XN2mt construct (mut)
werecotransfectedintoSL2cells
in triplicate along with the indi-
cated amounts of either the
pPacSp1 expression plasmid or
the empty pPacU expression vec-
tor. The pCMV bgal plasmid was
also cotransfected to normalize
for transfection efficiency. Rela-
tive reporter activity was calcu-
lated as in Fig 4, with the activity
of the pGL2:SV40 promoter plas-
mid assigned a value of 1; error
bars indicate 6 SE.
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contained within approximately 125 bp of the transcriptional
initiation sites, and that deletion of the region between bases
2124 and 283 results in a marked loss in activity. This region
contains several possible binding sites for the transcription
factor Sp1, but Sp1 seems to bind only to the 293/284 site with
high affinity, and mutation of this site results in a drop in
promoter activity to basal levels. Taken together, the data
presented here and previously published suggest that selective
Sp1 binding to the 293/284 site must cooperate with presumed
upstream factors to control c-kit promoter activation in a cell
type–speciﬁc manner. Characterization of the binding sites and
identiﬁcation of these upstream factors should be a subject for
future investigation.
ACKNOWLEDGMENT
We thank Barbara Armstrong and Julie Litz for excellent technical
assistance during the course of this study, Dr Robert Tjian for donating
the pPacU and pPacSp1 plasmids, and Dr Richard Moran for donating the
SL2 cells.
REFERENCES
1. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S,
Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human
proto-oncogene c-kit:Anew cell surface receptor tyrosine kinase for an
unidentiﬁed ligand. EMBO J 6:3341, 1987
2. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman
L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD: A new acute
transforming feline retrovirus and relationship of its oncogene v-kit
with the protein kinase gene family. Nature 320:415, 1986
3. Chabot B, Stephenson DA, ChapmanVM, Besmer P, BernsteinA:
The proto-oncogene c-kit encoding a transmembrane tyrosine kinase
receptor maps to the mouse W locus. Nature 335:88, 1988
4. Geissler EN, Ryan MA, Housman DE: The dominant-white
spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell
55:185, 1988
5. Williams DE, Eisenman J, BairdA, Rauch C, Van Ness K, March
CJ, Park LS, Martin U, Mochizuki DY, Boswell HS, Burgess GS,
Cosman D, Lyman SD: Identiﬁcation of a ligand for the c-kit
proto-oncogene. Cell 63:167, 1990
6. Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW,
Wellner D, Leder P, Besmer P: The hematopoietic growth factor KL is
encoded by the Sl locus and is the ligand of the c-kit receptor, the gene
product of the W locus. Cell 63:225, 1990
7. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA,
Cosman D, Anderson D, Lyman SD, Williams DE: Mast cell growth
factor maps near the steel locus on mouse chromosome 10 and is deleted
in a number of steel alleles. Cell 63:175, 1990
8. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH,
Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jacobsen
FW, Langley KE, Smith KA,TakeishiT, Cattanach BM, Galli SJ, Suggs
SV: Stem cell factor is encoded at the Sl locus of the mouse and is the
ligand for the c-kit tyrosine kinase receptor. Cell 63:213, 1990
9. Russell ES: Hereditary anemias of the mouse: a review for
geneticists.Adv Genet 20:357, 1979
10. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH,
Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA, Birkett NC, Smith
KA, Johnson MJ, Parker VP, Flores JC, Patel AC, Fisher EF, Erjavec
HO, Herrera CJ, Wypych J, Sachdev RK, Pope JA, Leslie I, Wen D, Lin
C-H, Cupples RL, Zsebo KM: Primary structure and functional
expression of rat and human stem cell factor DNAs. Cell 63:203, 1990
11. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J,
Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D,Williams DE:
Molecular cloning of mast cell growth factor, a hematopoietin that is
active in both membrane bound and soluble forms. Cell 63:235, 1990
12. Ratajczak MZ, Luger SM, DeRiel K, Abrahm J, Calabretta B,
Gewirtz AM: Role of the KIT protooncogene in normal and malignant
human hematopoiesis. Proc NatlAcad Sci USA89:1710, 1992
13. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G: Coexpression
of the c-kit receptor and the stem cell factor in gynecological tumors.
Cancer Res 54:3049, 1994
14. Toyota M, HinodaY, TakaokaA, MakiguchiY, Takahashi T, Itoh
F, Imai K, Yachi A: Expression of c-kit and Kit ligand in human colon
carcinoma cells. Tumour Biol 14:295, 1993
15. Hines SJ, Organ C, Kornstein MJ, Krystal GW: Coexpression of
the c-kit and stem cell factor genes in breast carcinomas. Cell Growth
Differ 6:769, 1995
16. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC:
Expression of stem cell factor and c-kit in human neuroblastoma. The
Children’s Cancer Group. Blood 84:3465, 1994
17. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K,
AriyoshiY, Takahashi T: Preferential expression of c-kit protooncogene
transcripts in small cell lung cancer. Cancer Res 51:2416, 1991
18. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y,
Takagi H, Takahashi T: Coexpression of the stem cell factor and the
c-kit genes in small-cell lung cancer. Oncogene 6:2291, 1991
19. Plummer H III, Catlett J, Leftwich J, Armstrong B, Carlson P,
Huff T, Krystal G: c-myc expression correlates with suppression of c-kit
protooncogene expression in small cell lung cancer cell lines. Cancer
Res 53:4337, 1993
20. Rygaard K, Nakamura T, Spang-Thomsen M: Expression of the
proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth
factor/scatter factor and stem cell factor, in SCLC cell lines and
xenografts. Br J Cancer 67:37, 1993
21. Krystal GW, Hines SJ, Organ CP:Autocrine growth of small cell
lung cancer mediated by coexpression of c-kit and stem cell factor.
Cancer Res 56:370, 1996
22. Pugh BF, Tjian R: Mechanism of transcriptional activation by
Sp1: Evidence for coactivators. Cell 61:1187, 1990
23. Briggs MR, Kadonaga JT, Bell SP, Tjian R: Puriﬁcation and
biochemical characterization of the promoter-speciﬁc transcription
factor, Sp1. Science 234:47, 1986
24. Kriwacki RW, Schultz SC, Steitz TA, Caradonna JP: Sequence-
speciﬁc recognition of DNA by zinc-ﬁnger peptides derived from the
transcription factor Sp1. Proc NatlAcad Sci USA89:9759, 1992
25. Hagen G, Dennig J, Preiss A, Beato M, Suske G: Functional
analyses of the transcription factor SP4 reveal properties distinct from
Sp1 and Sp3. J Biol Chem 270:24989, 1995
26. Kingsley C, Winoto A: Cloning of GT box-binding proteins: A
novel Sp1 multigene family regulating T-cell receptor gene expression.
Mol Cell Biol 12:4251, 1992
27. Hagen G, Muller S, Beato M, Suske G: Sp1-mediated transcrip-
tional activation is repressed by Sp3. EMBO J 13:3843, 1994
28. Udvadia AJ, Templeton DJ, Horowitz JM: Functional interac-
tions between the retinoblastoma (Rb) protein and Sp-family members:
Superactivation by Rb requires amino acids necessary for growth
suppression. Proc NatlAcad Sci USA92:3953, 1995
29. Zhao L, Chang LS:The human POLD1 gene. Identiﬁcation of an
upstream activator sequence, activation by Sp1 and Sp3, and cell cycle
regulation. J Biol Chem 272:4869, 1997
30. Dynan WS, Tjian R: Isolation of transcription factors that
discriminate between different promoters recognized by RNApolymer-
ase II. Cell 32:669, 1983
31. Gidoni D, Dynan WS, Tjian R: Multiple speciﬁc contacts
between a mammalian transcription factor and its cognate promoters.
Nature 312:409, 1984
32. Gidoni D, Kadonaga JT, Barrera-Saldana H, Takahashi K,
4148 PARK, PLUMMER, AND KRYSTAL
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From Chambon P, Tjian R: Bidirectional SV40 transcription mediated by
tandem Sp1 binding interactions. Science 230:511, 1985
33. Yasuda H, Galli SJ, Geissler EN: Cloning and functional analysis
of the mouse c-kit promoter. Biochem Biophys Res Commun 191:893,
1993
34. Giebel LB, Strunk KM, Holmes SA, Spritz RA: Organization
and nucleotide sequence of the human KIT (mast/stem cell growth
factor receptor) proto-oncogene. Oncogene 7:2207, 1992
35. Yamamoto K, Tojo A, Aoki N, Shibuya M: Characterization of
the promoter region of the human c-kit proto-oncogene. Jpn J Cancer
Res 84:1136, 1993
36. Vandenbark GR, Chen Y, Friday E, Pavlik K, Anthony B,
deCastro C, Kaufman RE: Complex regulation of human c-kit transcrip-
tion by promoter repressors, activators, and speciﬁc myb elements. Cell
Growth Differ 7:1383, 1996
37. Tsujimura T, Morii E, Nozaki M, Hashimoto K, Moriyama Y,
Takebayashi K, Kondo T, Kanakura Y, Kitamura Y: Involvement of
transcription factor encoded by the mi locus in the expression of c-kit
receptor tyrosine kinase in cultured mast cells of mice. Blood 88:1225,
1996
38. Ratajczak,MZ, Perrotti D, Melotti P, Powzaniuk M, Calabretta
B, Onodera K, Kregenow DA, Machalinski B, Gewirtz AM: Myb and
Ets proteins are candidate regulators of c-kit expression in human
hemopoietic cells. Blood 91:1934, 1998
39. Frohman MA, Dush MK, Martin GR: Rapid production of
full-length cDNAs from rare transcripts: ampliﬁcation using a single
gene-speciﬁc oligonucleotide primer. Proc NatlAcad Sci USA85:8998,
1988
40. Davis LG, Dibner MD, Battey JF: Basic Methods in Molecular
Biology. NewYork, NY, Elsevier, 1986
41. Krystal GW, Armstrong BC, Battey JF: N-myc mRNA forms an
RNA-RNA duplex with endogenous antisense transcripts. Mol Cell
Biol 10:4180, 1990
42. Smale ST, Baltimore D:The ‘‘initiator’’as a transcription control
element. Cell 57:103, 1989
43. Javahery R, KhachiA, Lo K, Zenzie-Gregory B, Smale ST: DNA
sequence requirements for transcriptional initiator activity in mamma-
lian cells. Mol Cell Biol 14:116, 1994
44. Courey AJ, Tjian R: Analysis of Sp1 in vivo reveals multiple
transcriptional domains, including a novel glutamine-rich activation
domain. Cell 55:887, 1988
45. Nagle DL, Kozak CA, Mano H, Chapman VM, Bucan M:
Physical mapping of the Tec and Gabrb1 loci reveals that the Wsh
mutation on mouse chromosome 5 is associated with an inversion. Hum
Mol Genet 4:2073, 1995
46. Duttlinger R, Manova K, Berrozpe G, Chu TY, DeLeon V,
Timokhina I, Chaganti RS, Zelenetz AD, Bachvarova RF, Besmer P:
The Wsh and Ph mutations affect the c-kit expression proﬁle: c-kit
misexpression in embryogenesis impairs melanogenesis in Wsh and Ph
mutant mice. Proc NatlAcad Sci USA92:3754, 1995
47. Wariishi S, Miyahara K, Toda K, Ogoshi S, Doi Y, Ohnishi S,
Mitsui Y, Yui Y, Kawai C, Shizuta Y: A Sp1 binding site in the GC-rich
region is essential for a core promoter activity of the human endothelial
nitric oxide synthase gene. Biochem Biophys Res Commun 216:729,
1995
48. O’Leary KA, McQuiddy P, Kasper CB: Transcriptional regula-
tion of the TATA-less NADPH cytochrome P-450 oxidoreductase gene.
Arch Biochem Biophys 330:271, 1996
49. Dusing MR, Wiginton DA: Sp1 is essential for both enhancer-
mediated and basal activation of the TATA-less human adenosine
deaminase promoter. NucleicAcids Res 22:669, 1994
50. Kadonaga JT, Carner KR, Masiarz FR, Tjian R: Isolation of
cDNA encoding transcription factor Sp1 and functional analysis of the
DNAbinding domain. Cell 51:1079, 1987
51. Ji C, Casinghino S, McCarthy TL., Centrella M: Multiple and
essential Sp1 binding sites in the promoter for transforming growth
factor-b type I receptor. J Biol Chem 272:21260, 1997
52. Shingu T, Bornstein P: Overlapping Egr-1 and Sp1 sites function
in the regulation of transcription of the mouse thrombospondin 1 gene. J
Biol Chem 269:32551, 1994
53. Yang X, Fyodorov D, Deneris ES: Transcriptional analysis of
acetylcholine receptor a3 gene promoter motifs that bind Sp1 and AP2.
J Biol Chem 270:8514, 1995
54. Fischer KD, Haese A, Nowock J: Cooperation of GATA-1 and
Sp1 can result in synergistic transcriptional activation or interference. J
Biol Chem 268:23915, 1993
Sp1 REGULATES CORE c-kit PROMOTER ACTIVITY 4149
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From 